Erratum: Statins and musculoskeletal conditions, arthropathies, and injuries (JAMA Internal Medicine (2013) DOI: 10.1001/jamainternmed.2013.6184);Statins and musculoskeletal conditions, arthropathies, and injuries

JAMA Internal Medicine

Volumn 173, Issue 14, 2013, Pages 1-10

  Mansi, Ishak ^a,b,c,g   Frei, Christopher R ^d,e   Pugh, Mary Jo ^d,f   Makris, Una ^g   Mortensen, Eric M ^g  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTHROPATHY; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISLOCATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE STRAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPRAIN;

EID: 84880685940     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.10000     Document Type: Erratum

References (64)

1. Hoffman KB, Kraus C, DimbilM, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One. 2012;7(8):e42866. doi:10.1371/journal.pone.0042866.
2. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13): 1681-1690.
3. Marie I, Delafenêtre H, Massy N, Thuillez C, Noblet C; Network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum. 2008;59(3):367-372.
4. Carmont MR, Highland AM, Blundell CM, Davies MB. Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise. Phys Ther Sport. 2009;10(4):150-152.
5. Beri A, Dwamena FC, Dwamena BA. Association between statin therapy and tendon rupture: a case-control study. J Cardiovasc Pharmacol. 2009;53(5):401-404.
6. Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, Thompson PD. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 2007;100(1):152-153.
7. Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011;23(6): 612-619.
8. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94-102.
9. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625-633.
10. Mansi IA, Mortensen EM, Pugh MJ,Wegner M, Frei CR. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis. Am J Med Sci. 2013;345(5):343-348.
11. Baker JF,Walsh P, Mulhall KJ. Statins: a potential role in the management of osteoarthritis? Joint Bone Spine. 2011;78(1):31-34.
12. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6): 393-403.
13. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051-2057.
14. Luhrman S, Lehr E, Hefflin C, Saund N. Interface control document describing the case management exchange from BEA to MDR and M2 baseline: Defense Health Services Systems program management. ICD-1300-6220-01. August 18, 2008 edition. Falls Church, VA. http://www.tricare.mil/ocfo/bea/downloads/icd%201300- 6220-01%20approved%20case%20management%20icd%20(2).doc. 2008.
15. Guide to DoD researchers on using MHS data. Office of the Assistant Secretary of Defense for Health Affairs-TRICARE Management Activity, Human Research Protection Program. October 12, 2012. http://www.tricare.mil/tma/ privacy/hrpp. Accessed October 20, 2012.
16. M2 MHS management analysis and reporting tool: executive information and decision support (EIDS) for the Military Health System. http://www.tricare.mil/ mhsophsc/mhs-supportcenter/Library/1-M2.pdf. Accessed January 7, 2012.
17. Gantt CJ, Neely JA, Villafana IA, Chun CS, Gharabaghli SM. Analysis of weight and associated health consequences of the active duty staff at a major naval medical center. Mil Med. 2008;173(5): 434-440.
18. George SZ, Childs JD, Teyhen DS, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in theMilitary (POLM) cluster randomized trial. BMC Med. 2011;9(1):128. doi:10.1186/1741-7015-9-128.
19. Enewold L, Brinton LA, McGlynn KA, Zahm SH, Potter JF, Zhu K. Oral contraceptive use among women in themilitary and the general U.S. population. JWomens Health (Larchmt). 2010;19(5):839-845.
20. Moniz C. Outpatient workload (RVU) predictors: age, gender & beneficiary category. Baltimore, MD: US Army Medical Department Center and School, report number 34-08. 2008:1-47. http://www.dtic.mil/dtic/tr/fulltext/u2/ a493965.pdf. Accessed January 11, 2012.
21. Kugler J. Military health system patient centered medical home guide. Tricare-Office of the Chief Medical Officer, Department of Defense. June 2011. http://www.tricare.mil/tma/ocmo/download/MHSPCMHGuide.pdf. Accessed January 11, 2012.
22. Clinical Classifications Software (CCS) for ICD-9-CM. US Agency for Healthcare Research and Quality. 2012. http://www.hcup-us.ahrq.gov/ toolssoftware/ccs/ccs.jsp. Accessed January 1, 2012.
23. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
24. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J Ambul Care Manage. 2004;27(3):281-295.
25. Gibson D, Helmick K, JaffeM, et al. Traumatic brain injury care in the Department of Defense. 2009. http://www.docstoc.com/docs/38360529/traumatic- brain-injury-care-in-the-department-ofdefense. Accessed July 12, 2012.
26. Tan CP, Ng A, Civil I. Co-morbidities in trauma patients: common and significant. N Z Med J. 2004;117(1201):U1044. http://journal.nzma.org.nz/ journal/117-1201/1044/content.pdf. Accessed December 19, 2011.
27. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8): 1182-1186.
28. Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med. 2012;125(2):176-182.
29. Caplan L, Pittman CB, Zeringue AL, et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc. 2010;85(4):341-348.
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
31. FDA Drug Safety Communication. New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed June 15, 2011.
32. Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2(4):358-377.
33. Leuven E, Sianesi B. PSMATCH2: stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing: version 4.0.5 ed. 2003. http://ideas.repec.org/c/boc/bocode/s432001. html. Accessed July 7, 2011.
34. Bender R, Blettner M. Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. 2002;55(5):525-530.
35. Scranton RE, YoungM, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005;165(17):2007-2012.
36. Mansi I, Pugh MJ, Frei CR, Mortensen EM. Association of psychological diseases with statin use: a propensity-score cohort analysis [published online April 26, 2013]. Pharmacotherapy. doi:10.1002/phar.1272.
37. Steinberg D. Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J AmColl Cardiol. 2010;56(8):627-629.
38. Forrester JS. Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol. 2010;56(8):630-636.
39. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21(4): 324-328.
40. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172(15):1180-1182.
41. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96-103.
42. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197. doi.org/10.1136/bmj.c2197.
43. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4): 525-528.
44. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206-1210.
45. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA. 1990;264(23):2992.
46. Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci. 2005;88(2):551-561.
47. Jordan K, Clarke AM, Symmons DP, et al. Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract. 2007;57(534):7-14.
48. Haskell SG, Ning Y, Krebs E, et al. Prevalence of musculoskeletal conditions in female and male veterans in 7 years after return from deployment in Operation Enduring Freedom/Operation Iraqi Freedom. Clin J Pain. 2012;28(2):163-167.
49. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J AmColl Cardiol. 2008;51(4): 415-426.
50. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363(9412):892-894.
51. Golomb BA, Evans MA. Statin adverse effect: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
52. Yu JG, Sewright K, Hubal MJ, et al. Investigation of gene expression in C2C12 myotubes following simvastatin application and mechanical strain. J Atheroscler Thromb. 2009;16(1):21-29.
53. Phillips PS, Haas RH, Bannykh S, et al; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137(7):581-585.
54. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizingmyopathy associated with statins. Muscle Nerve. 2010;41(2):185-190.
55. Needham M, Fabian V, KnezevicW, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194-200.
56. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713-721.
57. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dL with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J AmColl Cardiol. 2011, 57 (16): 1666-1675
58. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83(6):687-700.
59. Golomb BA. Do statins reduce the risk of infection? BMJ. 2011;343:d7134. doi.org/10.1136/bmj.d7134.
60. Curtiss FR, Fairman KA. Tough questions about the value of statin therapy for primary prevention: did JUPITER miss the moon? J Manag Care Pharm. 2010;16(6):417-423.
61. Haddock CK, PostonWS, Klesges RC, Talcott GW, Lando H, Dill PL. An examination of body weight standards and the association between weight and health behaviors in the United States Air Force. Mil Med. 1999;164(1):51-54.
62. Ode JJ, Pivarnik JM, Reeves MJ, Knous JL. Body mass index as a predictor of percent fat in college athletes and nonathletes. Med Sci Sports Exerc. 2007;39(3):403-409.
63. Buchbinder R, Goel V, Bombardier C. Lack of concordance between the ICD-9 classification of soft tissue disorders of the neck and upper limb and chart review diagnosis: one steel mill's experience. Am J Ind Med. 1996;29(2):171-182.
64. Gray D,Ward A, Underwood P, Fatovich B, Winkler R. Morbidity coding in general practice. FamPract. 1989;6(2):92-97.